Filing Details
- Accession Number:
- 0000899243-19-013261
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-13 17:03:50
- Reporting Period:
- 2019-05-09
- Accepted Time:
- 2019-05-13 17:03:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1563880 | Trevi Therapeutics Inc. | TRVI | Pharmaceutical Preparations (2834) | 450834299 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1641348 | Omega Fund V Gp Manager, Ltd. | 888 Boylston Street, Suite 1111 Boston MA 02199 | No | No | Yes | No | |
1641354 | Omega Fund V, L.p. | 888 Boylston Street, Suite 1111 Boston MA 02199 | No | No | Yes | No | |
1641355 | Omega Fund V Gp, L.p. | 888 Boylston Street, Suite 1111 Boston MA 02199 | No | No | Yes | No | |
1758535 | Guyer Anna Mitsak | 888 Boylston Street, Suite 1111 Boston MA 02199 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-05-09 | 582,408 | $0.00 | 582,408 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2019-05-09 | 481,000 | $10.00 | 1,063,408 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series C Preferred Stock | Disposition | 2019-05-09 | 5,136,986 | $0.00 | 582,408 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct |
Footnotes
- On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Annie Mitsak, a member of the Issuer's board of directors, has no voting or investment control over any of the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Annie Mitsak disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.